Investment Strategy

Healthy growth for Latin America: Tapping the region’s healthcare sector for economic gains

Introduction

Latin America’s healthcare sector is navigating a period of significant transformation. Demand for healthcare services is increasing, while persistent challenges in infrastructure, funding and access hinder the region’s ability to meet this demand effectively. However, these intersecting trends also present an opportunity. With investments and policy reforms, Latin America can address these challenges, fostering economic growth and improved quality of life for its citizens.

Current landscape and challenges in healthcare

Healthcare infrastructure, accessibility and disparities

Over the last few decades, healthcare access and affordability in Latin America have improved significantly. Life expectancy at birth has risen from 71 to 74 years, although this increase falls short of the OECD average.1 Similarly, out-of-pocket healthcare expenses have dropped from over 40% to approximately 28%,2 underscoring enhanced affordability (Fig 1).

Out-of-pocket expenditure as a % of current health expenditure in Latin America & Caribbean

Source: World Development Indicators. Data as of December 16th 2024.
However, these positive developments mask underlying disparities in access to and quality of care. The region’s healthcare infrastructure remains insufficient. The average number of physicians (two per 1,000 people) and nurses (3.6 per 1,000) are well below the OECD standards of 3.5 and 10.3, respectively (Fig 2).Only Argentina and Uruguay surpass these benchmarks. Across Colombia, Peru, Mexico and Uruguay, only a third of adults report having access to high-quality care.4

Medical doctors per 1,000 people

Source: WHO. Data as of January 25th 2025.

Income inequality exacerbates these challenges. In Colombia, for instance, 32% of the poorest citizens reported barriers to healthcare access before the pandemic, compared with just 19% of the wealthiest.5 Excluding Argentina, Costa Rica, Mexico and Uruguay, private healthcare expenditure has been increasing across the region.6 Currently, government and compulsory health insurance spending in Latin America averages just 57% of total health expenditure, significantly below the OECD average of 74%.7 This reflects the higher rate of out-of-pocket spending in the region, which contributes to a two-tiered system.

Inequities are also evident in urban-rural divides: in 2020, 21% of rural households in Latin America reported an inability to access healthcare, compared with 16% of urban households.8 This gap underscores the critical need for more equitable distribution of healthcare resources.

Aging population and healthcare demand

Latin America’s population is aging rapidly (Fig 3). By 2050, the elderly population will more than double, with those aged 60 and older accounting for over 25% of the region’s total population.9 This demographic shift will significantly alter the region’s workforce and increase demand for healthcare services, particularly in long-term and geriatric care, chronic disease management, and palliative care.

Median age of population, Latin America and the Caribbean

Source: UN Population Division. Published 2024.

Non-communicable diseases (NCDs)—such as cardiovascular diseases, diabetes and cancer—are already the leading cause of mortality in the region, responsible for 77% of deaths.10 Aging is directly linked to the prevalence of NCDs, and it has counteracted the progress made through successful public health efforts to reduce NCD incidence.11 Specialized geriatric care will be required to support the aging population’s needs, particularly for preventing, treating and managing NCDs, as the population continues to age throughout Latin America in the coming years. Yet, its availability remains limited.12 Efforts to upskill healthcare workers in geriatrics could help address this shortfall while creating much-needed employment opportunities in the sector.

Healthcare as a driver for economic growth

The economic case for better healthcare systems

Improved healthcare systems not only save lives but also drive economic prosperity. Econometric research suggests that an additional average year of life expectancy is associated with a 2.4% increase in economic growth for a country.13 For lower-income countries, this boost is even more pronounced, as healthier populations contribute to demographic transitions and long-term growth. For wealthier nations, the connection lies in enhanced productivity—healthier workers are more productive, and older adults who maintain better health can continue to participate in the economy longer, supporting consumer spending and reducing dependency costs.

The aging population as a challenge and opportunity

Despite the headwinds associated with aging, particularly when it comes to the workforce, this population also represents a powerful economic force. Globally, the 50+ demographic is projected to account for US$118trn—or 39%—of global GDP by 2050.14 In Latin America, this group’s contributions will be substantial: by 2050, older adults will generate 48% of Brazil’s GDP, 47% of Argentina and Chile’s GDP, and 35% of Mexico’s GDP.

To harness this potential, targeted investments in elderly care infrastructure through facilities, training and technology are essential. Supporting older adults’ active participation in the economy could mitigate the high costs associated with preventable diseases while promoting a healthy lifespan extension. This, in turn, promotes consumer spending among the aging population.

Healthcare and biotech’s growth potential

Latin America’s healthcare and biotech sectors hold untapped economic potential. The biopharma market, currently valued at US$32.4bn, is projected to reach US$51.4bn by 2029.15 Despite this growth, the pharmaceuticals sector contributes no more than 1% of GDP in any of the countries in Latin America.16 The region accounts for just 4% of global pharmaceutical revenue, far below its 8.3% share of the global population.17

The region’s fragmented pharmaceutical production highlights expansion opportunities. While countries like Mexico and Uruguay produce over 40% of their domestic pharmaceutical needs, others like Chile and Peru meet just 15% and 12%, respectively.18 Enhancing local production capabilities could reduce reliance on imports and foster economic resilience.

Biotech start-ups are also gaining traction, leveraging the region’s rich biodiversity and talent for research and development and advancing technologies like artificial intelligence-driven diagnostics. By 2030, Latin America’s biotech sector is expected to surpass US$210m—a small but rapidly growing proportion of the overall biopharma sector.19

Health innovation and technology are burgeoning fields as well. Over the past decade, more than 1,200 health tech companies have emerged in Latin America, with Brazil leading the charge and funding peaking at over US$650m in 2022 (Fig 4).20, 21 However, the notable decrease in 2023, particularly in the health space, was driven by a correction in overall venture capital funding amid global high valuations and rate hikes. Telemedicine, catalysed by the covid-19 pandemic, is particularly promising. During this period, telehealth and digital health solutions gained rapid, wide acceptance across the region. For example, in Uruguay, 86% of early covid-19 cases were managed remotely, facilitated by supportive legislation (Fig 5).22 Consumer demand for telehealth is robust—48% and 41% of individuals in Latin America say they prefer virtual or at-home care for follow-up and low-complexity situations, respectively.23

Healthtech funding, Latin America and the Caribbean, US$ m

Source: IDB; HolonIQ, Published December 1st 2023.

Proportion of early covid-19 cases in Uruguay treated using telemedicine

Source: PAHO. Data accessed on November 18th 2024.

This demand extends beyond telehealth to a range of digital health solutions—81% of people in the region express willingness to pay for wellness apps, including 88% of Mexicans. One example of a firm taking advantage of this new environment in the region is Nilo Saúde in Brazil.24 The company offers care coordination and patient health solutions for health services networks and raised US$10m in series A funding from a team of investors in 2022.25

Economic and policy considerations for promoting health and longevity

 

There are structural changes that would help promote improved health and longevity across the region while fostering a strong entrepreneurial environment in Latin America:

Increasing healthcare investments

Reaping the rewards of good health will require investments into healthcare systems. The Pan American Health Organization recommends that countries allocate at least 6% of GDP to healthcare, but only a few, including Cuba and Uruguay, meet this target.26 Increased investment is critical to expanding access and addressing future challenges, but this target will be particularly difficult to achieve given the fiscal headwinds and high debt levels in many Latin American countries.27

Enhancing health information systems

Effective healthcare systems require robust data infrastructure. Improved health information systems would enable policymakers and practitioners to assess care quality and outcomes more effectively, driving continuous improvement.28

Promoting digital health solutions

The adoption of digital health tools, such as telemedicine, represents a transformative opportunity. These technologies can bridge gaps in healthcare access, particularly in underserved rural areas, while fostering growth in the region’s health tech sector.29

Addressing social determinants of health

Health disparities are often rooted in broader social inequities. Targeting the social determinants of health—such as income inequality, education and housing—could significantly reduce these disparities.30 Policymakers should prioritise initiatives that address these underlying factors to promote a more equitable healthcare system.

Seizing the healthcare opportunity


Latin America’s healthcare sector stands at a pivotal moment. While progress in access and affordability has been significant, the region must address persistent disparities and prepare for growing healthcare demands. By investing in healthcare infrastructure, workforce development and technological innovation, Latin America can build a resilient system capable of meeting these challenges.

Moreover, the healthcare sector offers a dual opportunity: improved public health and substantial economic growth. Advancing health innovation and addressing the social determinants of health will not only enhance the quality of life across the region but also lay the foundation for long-term prosperity.

Latin America’s path forward is clear. By seizing this moment, the region can transform its healthcare challenges into a cornerstone of sustainable development and economic opportunity.

1 https://data.worldbank.org/indicator/SP.DYN.LE00.IN?locations=ZJ; https://www.oecd.org/en/publications/health-at-a-glance-latin-america-and-the-caribbean-2023_532b0e2d-en.html

2 https://data.worldbank.org/indicator/SH.XPD.OOPC.CH.ZS?locations=ZJ

3 https://www.oecd.org/en/publications/2023/04/health-at-a-glance-latin-america-and-the-caribbean-2023_7ba284d7.html

4 https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(23)00488-6/fulltext

5 https://www.scielosp.org/article/rpsp/2020.v44/e11/#

6 https://www.lse.ac.uk/business/consulting/assets/documents/latin-america-healthcare-system-overview-report-english.pdf

7 https://www.oecd.org/en/publications/health-at-a-glance-latin-america-and-the-caribbean-2023_532b0e2d-en.html

8 https://www.oecd.org/en/publications/2023/04/health-at-a-glance-latin-america-and-the-caribbean-2023_7ba284d7.html

9 https://www.oecd.org/en/publications/health-at-a-glance-latin-america-and-the-caribbean-2023_532b0e2d-en.html

10 https://www.oecd.org/en/publications/2023/04/health-at-a-glance-latin-america-and-the-caribbean-2023_7ba284d7.html

11 https://www.sciencedirect.com/science/article/pii/S2667193X23000571

12 https://pmc.ncbi.nlm.nih.gov/articles/PMC9384165/

13 https://link.springer.com/article/10.1007/s00181-022-02226-4

14 https://www.aarp.org/content/dam/aarp/research/surveys_statistics/econ/2022/global-longevity-economy-report.doi.10.26419-2Fint.00052.001.pdf

15 https://www.marketdataforecast.com/market-reports/latin-america-bio-pharmaceuticals-market

16 https://openknowledge.worldbank.org/server/api/core/bitstreams/353c099b-8aae-58f5-8a6d-c07eef593556/content

17 https://publications.iadb.org/en/publications/english/viewer/Health-Innovation--Technology-in-Latin-America--the-Caribbean.pdf

18 https://publications.iadb.org/en/publications/english/viewer/Health-Innovation--Technology-in-Latin-America--the-Caribbean.pdf

19 https://www.grandviewresearch.com/horizon/outlook/biotechnology-market/latin-america

20 https://publications.iadb.org/en/publications/english/viewer/Health-Innovation--Technology-in-Latin-America--the-Caribbean.pdf

21 https://news.crunchbase.com/venture/latin-america-startup-funding-eoy-2024/

22 https://www.paho.org/es/historias/telemedicina-uruguay-estrategia-que-lleg

23 https://www.mckinsey.com/industries/healthcare/our-insights/healthcare-in-latin-america-what-are-consumers-looking-for

24 https://www.nilosaude.com.br/

25 https://latamlist.com/brazilian-healthtech-nilo-saude-raises-10m-in-a-series-a-latamlist/

26 https://www.thedialogue.org/analysis/latin-americas-lagging-economies-and-setting-priorities-for-health-investment/

27 https://americasquarterly.org/article/latin-americas-renewed-fiscal-challenges/

28 https://www.oecd.org/en/publications/health-at-a-glance-latin-america-and-the-caribbean-2023_532b0e2d-en.html

29 https://publications.iadb.org/en/publications/english/viewer/Health-Innovation--Technology-in-Latin-America--the-Caribbean.pdf

30 https://oxfordre.com/economics/display/10.1093/acrefore/9780190625979.001.0001/acrefore-9780190625979-e-246

KEY RISKS

Important Information

This material is for informational purposes only, and may inform you of certain products and services offered by private banking businesses, part of JPMorgan Chase & Co. (“JPM”). Products and services described, as well as associated fees, charges and interest rates, are subject to change in accordance with the applicable account agreements and may differ among geographic locations. Not all products and services are offered at all locations. Please read all Important Information.

General Risks & Considerations

Any views, strategies or products discussed in this material may not be appropriate for all individuals and are subject to risks. Investors may get back less than they invested, and past performance is not a reliable indicator of future results. Asset allocation/diversification does not guarantee a profit or protect against loss. Nothing in this material should be relied upon in isolation for the purpose of making an investment decision. You are urged to consider carefully whether the services, products, asset classes (e.g., equities, fixed income, alternative investments, commodities, etc.) or strategies discussed are suitable to your needs. You must also consider the objectives, risks, charges, and expenses associated with an investment service, product or strategy prior to making an investment decision. For this and more complete information, including discussion of your goals/situation, contact your J.P. Morgan team.

Non-Reliance

Certain information contained in this material is believed to be reliable; however, JPM does not represent or warrant its accuracy, reliability or completeness, or accept any liability for any loss or damage (whether direct or indirect) arising out of the use of all or any part of this material. No representation or warranty should be made with regard to any computations, graphs, tables, diagrams or commentary in this material, which are provided for illustration/ reference purposes only. The views, opinions, estimates and strategies expressed in this material constitute our judgment based on current market conditions and are subject to change without notice. JPM assumes no duty to update any information in this material in the event that such information changes. Views, opinions, estimates and strategies expressed herein may differ from those expressed by other areas of JPM, views expressed for other purposes or in other contexts, and this material should not be regarded as a research report. Any projected results and risks are based solely on hypothetical examples cited, and actual results and risks will vary depending on specific circumstances. Forward-looking statements should not be considered as guarantees or predictions of future events.

Nothing in this document shall be construed as giving rise to any duty of care owed to, or advisory relationship with, you or any third party. Nothing in this document shall be regarded as an offer, solicitation, recommendation or advice (whether financial, accounting, legal, tax or other) given by J.P. Morgan and/or its officers or employees, irrespective of whether or not such communication was given at your request. J.P. Morgan and its affiliates and employees do not provide tax, legal or accounting advice. You should consult your own tax, legal and accounting advisors before engaging in any financial transactions.

Latin America can transform its healthcare challenges into a cornerstone of sustainable development and economic opportunity.

you may also like

Apr 4, 2025

5 key strategies to fortify portfolios

Experience the full possibility of your wealth

We can help you navigate a complex financial landscape. Reach out today to learn how.

Contact us

LEARN MORE About Our Firm and Investment Professionals Through FINRA BrokerCheck

 

To learn more about J.P. Morgan’s investment business, including our accounts, products and services, as well as our relationship with you, please review our J.P. Morgan Securities LLC Form CRS and Guide to Investment Services and Brokerage Products

 

JPMorgan Chase Bank, N.A. and its affiliates (collectively "JPMCB") offer investment products, which may include bank-managed accounts and custody, as part of its trust and fiduciary services. Other investment products and services, such as brokerage and advisory accounts, are offered through J.P. Morgan Securities LLC ("JPMS"), a member of FINRA and SIPC. Insurance products are made available through Chase Insurance Agency, Inc. (CIA), a licensed insurance agency, doing business as Chase Insurance Agency Services, Inc. in Florida. JPMCB, JPMS and CIA are affiliated companies under the common control of JPMorgan Chase & Co. Products not available in all states.

 

Please read the Legal Disclaimer for J.P. Morgan Private Bank regional affiliates and other important information in conjunction with these pages.

INVESTMENT AND INSURANCE PRODUCTS ARE: • NOT FDIC INSURED • NOT INSURED BY ANY FEDERAL GOVERNMENT AGENCY • NOT A DEPOSIT OR OTHER OBLIGATION OF, OR GUARANTEED BY, JPMORGAN CHASE BANK, N.A. OR ANY OF ITS AFFILIATES • SUBJECT TO INVESTMENT RISKS, INCLUDING POSSIBLE LOSS OF THE PRINCIPAL AMOUNT INVESTED

Bank deposit products, such as checking, savings and bank lending and related services are offered by JPMorgan Chase Bank, N.A. Member FDIC.

Not a commitment to lend. All extensions of credit are subject to credit approval.

Equal Housing Lender Icon